Summary: Axsome Therapeutics Inc presented data at NEI Congress 2024 on solriamfetol’s impact on excessive daytime sleepiness and cognitive function in patients with obstructive sleep apnea and narcolepsy. These findings, part of Axsome’s broader research portfolio, included … [Read more...]
Axsome to Showcase Solriamfetol Research on Daytime Sleepiness and Cognition in OSA and Narcolepsy
Summary: At Psych Congress 2024, Axsome Therapeutics will present new research on solriamfetol, focusing on its effectiveness for managing excessive daytime sleepiness and cognitive impairment in patients with obstructive sleep apnea (OSA) and narcolepsy. These studies, part of … [Read more...]